AGM Statement
No summary for this filing – the full text is below.
Select text to share a quote on X · sign in to keep highlights & notes in your SVNS notes
Solvonis Therapeutics plc (LSE: SVNS), a clinical-stage biopharmaceutical company developing novel medicines for addiction and mental health disorders, announces that all resolutions proposed at its Annual General Meeting ("AGM") held earlier today were duly passed. A summary of the resolutions is provided at the end of this announcement.
This year's AGM marks a significant milestone in the Company's growth trajectory. Following the successful completion of the acquisition of Awakn Life Sciences on 28 May 2025, Solvonis has rapidly established itself as a leading European innovator in the development of precision neuropsychiatric therapeutics.
The combined company now benefits from a high-quality pipeline of preclinical and clinical-stage assets targeting alcohol use disorder, post-traumatic stress disorder, and other complex neuropsychiatric conditions. These programmes, including lead candidate SVN-001, are underpinned by translational science, real-world evidence, and a regulatory strategy aligned with expedited pathways in key jurisdictions.
Integration activities are progressing in line with plan, with a focus on operational efficiency, disciplined capital deployment, and preparing lead programmes for Phase 3 readiness and partnering opportunities. Solvonis continues to advance a virtual biotech model, supported by a lean team and an expanding network of expert collaborators and CROs.
Anthony Tennyson, CEO of Solvonis Therapeutics, commented: "Today's AGM reflects strong shareholder support for our vision and execution. With the acquisition of Awakn now complete, we are strategically positioned to lead in transforming the treatment landscape for substance use and treatment-resistant mental health disorders across Europe and beyond. We are focused on delivering value through rigorous development, targeted commercial strategy, and partnerships that extend our reach and impact."
The Board remains committed to building a capital-efficient, data-driven, and licensing-led business capable of delivering meaningful therapeutic advances and long-term value creation.
Further updates on programme progress and strategic initiatives will be provided in due course.
As noted, all resolutions proposed at the meeting were passed. The results of voting on each resolution are summarised below:
| Resolution | Votes for | For % | Votes against | Against % | Votes total | Votes withheld |
|---|---|---|---|---|---|---|
| Resolution 1 | 600,321,074 | 99.90% | 572,816 | 0.10% | 600,893,890 | 2,000 |
| Resolution 2 | 565,318,574 | 99.90% | 572,816 | 0.10% | 565,891,390 | 35,004,500 |
| Resolution 3 | 599,379,529 | 99.75% | 1,514,361 | 0.25% | 600,893,890 | 2,000 |
| Resolution 4 | 564,851,874 | 99.82% | 1,039,516 | 0.18% | 565,891,390 | 35,004,500 |
| Resolution 5 | 564,851,874 | 99.82% | 1,039,516 | 0.18% | 565,891,390 | 35,004,500 |
| Resolution 6 | 599,846,229 | 99.83% | 1,047,661 | 0.17% | 600,893,890 | 2,000 |
| Resolution 7 | 564,377,029 | 93.92% | 36,516,861 | 6.08% | 600,893,890 | 2,000 |
| Resolution 8 | 600,321,074 | 99.90% | 572,816 | 0.10% | 600,893,890 | 2,000 |
Notes:
- Resolutions 1 to 6 were passed as ordinary resolutions. Resolution 7 and 8 were passed as special resolutions.
- A vote withheld is not a vote in law and is not counted in the calculation of the proportion of votes "For" or "Against" any of the resolutions.
- As at the date of the GM, the Company's issued share capital consisted of 5,908,770,690 ordinary shares of £0.001 each.
Cleaned text: letterheads, contacts and legal notices removed. View the original announcement ↗ · Company filings. Not investment advice.